The next step toward GMP-grade production of engineered immune cells

Guido J J Kierkels; Trudy Straetemans; Moniek A de Witte; Jürgen Kuball

doi:10.1080/2162402X.2015.1076608

The next step toward GMP-grade production of engineered immune cells

Guido J J Kierkels, Trudy Straetemans, Moniek A de Witte, Jürgen Kuball

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.

Original language	English
Article number	e1076608
Journal	OncoImmunology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1080/2162402X.2015.1076608
Publication status	Published - Feb 2016

Keywords

Adoptive immunotherapy
allogeneic stem cell transplantation
GMP grade production
T cell subsets

Access to Document

10.1080/2162402X.2015.1076608

Cite this

@article{5227c209ed354e788a5d28be470197a5,

title = "The next step toward GMP-grade production of engineered immune cells",

abstract = "Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.",

keywords = "Adoptive immunotherapy, allogeneic stem cell transplantation, GMP grade production, T cell subsets",

author = "Kierkels, {Guido J J} and Trudy Straetemans and {de Witte}, {Moniek A} and J{\"u}rgen Kuball",

year = "2016",

month = feb,

doi = "10.1080/2162402X.2015.1076608",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "2",

}

TY - JOUR

T1 - The next step toward GMP-grade production of engineered immune cells

AU - Kierkels, Guido J J

AU - Straetemans, Trudy

AU - de Witte, Moniek A

AU - Kuball, Jürgen

PY - 2016/2

Y1 - 2016/2

N2 - Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.

AB - Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.

KW - Adoptive immunotherapy

KW - allogeneic stem cell transplantation

KW - GMP grade production

KW - T cell subsets

U2 - 10.1080/2162402X.2015.1076608

DO - 10.1080/2162402X.2015.1076608

M3 - Article

C2 - 27057450

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 2

M1 - e1076608

ER -

The next step toward GMP-grade production of engineered immune cells

Abstract

Keywords

Access to Document

Fingerprint

Cite this